Premium
Cumulative exposure to phthalates from phthalate‐containing drug products: a Danish population‐wide study
Author(s) -
Ennis Zandra Nymand,
Broe Anne,
Pottegård Anton,
Ahern Thomas P.,
Hallas Jesper,
Damkier Per
Publication year - 2018
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13614
Subject(s) - phthalate , dibutyl phthalate , diethyl phthalate , toxicology , medicine , environmental health , population , chemistry , biology , organic chemistry
Aims Up to 50‐fold higher levels of urinary phthalate metabolites have been observed in users of phthalate‐containing drug products compared with non‐users. This is of concern, as phthalates are suspected endocrine disrupters and have been associated with cancer development. This study aims to quantify annual cumulated phthalate exposure from drug products among users of phthalate‐containing oral medications in Denmark throughout the period of 2004–2016. Methods We conducted a Danish nationwide cohort study using The Danish National Prescription Registry and an internal database held by The Danish Medicines Agency. These databases hold information on drug products; date of dispensing, and the type and quantity of excipients in drugs with Danish marketing permission. We present the number of users over time and their distribution of exposure to enteric phthalate polymers and ortho‐phthalates. Results The annual number of individuals exposed to phthalate‐containing products declined during 2004–2016. The total number of individuals exposed to dibutyl phthalate declined from 21 499 in 2004 to 5400 in 2016. However, among those exposed, the median dibutyl phthalate exposure remained above European regulatory limit of exposure ranging between 380–1710 mg/year throughout the study period. Lithium‐products constituted the majority of dibutyl phthalate exposure. Diethyl phthalate exposure, mainly caused by erythromycin, theophylline and diclofenac products, did not exceed the EMA regulatory limit. Conclusion While the number of individuals exposed to phthalates from oral medications during 2004–2016 declined, the use of phthalate‐containing drugs is still considerable.